Compare Invesco DB Oil Fund (DBO) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Oil Fund vs ResMed Inc. — how do they compare? Invesco DB Oil Fund trades at $20.98, while ResMed Inc. trades at $225 (market cap $32.61B). The key difference: ResMed Inc. pays a 1.17% dividend while Invesco DB Oil Fund pays none, and Invesco DB Oil Fund is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| DBO | RMD | |
|---|---|---|
Sector | Commodities - Energy | Health |
52-Week High | $23.80 | $293.73 |
52-Week Low | $11.98 | $182.82 |
Market Cap | — | $32.61B |
Enterprise Value | — | $31.97B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBO trades at $21.03, up 0.86% with a bullish technical signal from moving averages. Recent news highlights oil market volatility due to Middle East tensions and OPEC demand forecast cuts. The stock shows neutral oscillator readings but strong moving average support, indicating underlying strength despite sector headwinds.
The outlook remains cautious due to oil market uncertainties, though technical momentum suggests near-term upside potential. Key risks include geopolitical supply disruptions and demand volatility, while institutional sentiment appears mixed with limited fundamental data available for analysis.
ResMed (RMD) trades at $225.17, up 2.33% today, reflecting strong recent earnings beats and robust fundamentals. The stock exhibits a bullish technical trend, supported by positive moving averages, with key resistance near $227. Financially, the company shows impressive growth, with Q4 2026 revenue reaching a record $1.5 billion (Reuters, 2026-08-07) and a net income margin of 26.94%. Recent strategic moves include the divestiture of the MatrixCare business to sharpen focus on core sleep and respiratory care markets.
The outlook for RMD is positive, driven by consistent earnings outperformance and strategic portfolio optimization. However, investors face risks from weaker-than-expected fiscal 2027 revenue guidance and competitive pressures in the medtech sector. The consensus price target of $235.00 (MarketBeat, 2026-08-09) suggests modest upside potential, supported by a majority analyst hold rating amid solid long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Invesco DB Oil Fund
DBO provides exposure to WTI crude oil prices through futures contracts. It is designed for investors seeking a way to invest in the performance of the fossil fuel market without purchasing physical oil barrels.
Read more on DBO →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
